A citation-based method for searching scientific literature

Benjamin Weide, Henning Zelba, Evelyna Derhovanessian, Annette Pflugfelder, Thomas K Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H J G Aarntzen, I Jolanda M de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec. J Clin Oncol 2012
Times Cited: 92







List of co-cited articles
730 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
35

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
25

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Benjamin Weide, Alexander Martens, Henning Zelba, Christina Stutz, Evelyna Derhovanessian, Anna Maria Di Giacomo, Michele Maio, Antje Sucker, Bastian Schilling, Dirk Schadendorf,[...]. Clin Cancer Res 2014
180
25

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Alexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, Jianda Yuan, Michael A Postow, Phillip Wong, Emanuela Romano, Amir Khammari, Brigitte Dreno, Mariaelena Capone,[...]. Clin Cancer Res 2016
362
21

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Steffen Walter, Toni Weinschenk, Arnulf Stenzl, Romuald Zdrojowy, Anna Pluzanska, Cezary Szczylik, Michael Staehler, Wolfram Brugger, Pierre-Yves Dietrich, Regina Mendrzyk,[...]. Nat Med 2012
579
19

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Jianda Yuan, Matthew Adamow, Brian A Ginsberg, Teresa S Rasalan, Erika Ritter, Humilidad F Gallardo, Yinyan Xu, Evelina Pogoriler, Stephanie L Terzulli, Deborah Kuk,[...]. Proc Natl Acad Sci U S A 2011
258
18

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, Igor Bondarenko, Steven O'Day, Jeffrey Weber, Claus Garbe, Celeste Lebbe, Jean-François Baurain, Alessandro Testori, Jean-Jacques Grob,[...]. N Engl J Med 2011
16

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
Naomi N Hunder, Herschel Wallen, Jianhong Cao, Deborah W Hendricks, John Z Reilly, Rebecca Rodmyre, Achim Jungbluth, Sacha Gnjatic, John A Thompson, Cassian Yee. N Engl J Med 2008
667
15

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
15

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
Henning Zelba, Benjamin Weide, Alexander Martens, Evelyna Derhovanessian, Jithendra Kini Bailur, Christina Kyzirakos, Annette Pflugfelder, Thomas K Eigentler, Anna Maria Di Giacomo, Michele Maio,[...]. Clin Cancer Res 2014
32
43

Final version of 2009 AJCC melanoma staging and classification.
Charles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, John F Thompson, Michael B Atkins, David R Byrd, Antonio C Buzaid, Alistair J Cochran, Daniel G Coit, Shouluan Ding,[...]. J Clin Oncol 2009
13

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Christiane Meyer, Laurène Cagnon, Carla M Costa-Nunes, Petra Baumgaertner, Nicole Montandon, Loredana Leyvraz, Olivier Michielin, Emanuela Romano, Daniel E Speiser. Cancer Immunol Immunother 2014
352
13

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
13

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
13

Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed,[...]. N Engl J Med 2013
11

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
11

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
10

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Paul F Robbins, Richard A Morgan, Steven A Feldman, James C Yang, Richard M Sherry, Mark E Dudley, John R Wunderlich, Azam V Nahvi, Lee J Helman, Crystal L Mackall,[...]. J Clin Oncol 2011
10

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Paola Filipazzi, Roberta Valenti, Veronica Huber, Lorenzo Pilla, Paola Canese, Manuela Iero, Chiara Castelli, Luigi Mariani, Giorgio Parmiani, Licia Rivoltini. J Clin Oncol 2007
519
10

Coordinated regulation of myeloid cells by tumours.
Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Vincenzo Bronte. Nat Rev Immunol 2012
10

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Jianda Yuan, Sacha Gnjatic, Hao Li, Sarah Powel, Humilidad F Gallardo, Erika Ritter, Geoffrey Y Ku, Achim A Jungbluth, Neil H Segal, Teresa S Rasalan,[...]. Proc Natl Acad Sci U S A 2008
263
10

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
10

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Yann Godet, Elizabeth Fabre, Magalie Dosset, Michele Lamuraglia, Emeline Levionnois, Patrice Ravel, Nadine Benhamouda, Aurélie Cazes, Françoise Le Pimpec-Barthes, Beatrice Gaugler,[...]. Clin Cancer Res 2012
72
12

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
9

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
Cornelis J M Melief, Sjoerd H van der Burg. Nat Rev Cancer 2008
396
9

Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj. Nat Rev Immunol 2009
9

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Isabel Poschke, Dimitrios Mougiakakos, Johan Hansson, Giuseppe V Masucci, Rolf Kiessling. Cancer Res 2010
309
9

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, Steven O'Day, Jeffrey S Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol,[...]. Clin Cancer Res 2009
9


T-helper-1-cell cytokines drive cancer into senescence.
Heidi Braumüller, Thomas Wieder, Ellen Brenner, Sonja Aßmann, Matthias Hahn, Mohammed Alkhaled, Karin Schilbach, Frank Essmann, Manfred Kneilling, Christoph Griessinger,[...]. Nature 2013
431
9


Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Alena Gros, Maria R Parkhurst, Eric Tran, Anna Pasetto, Paul F Robbins, Sadia Ilyas, Todd D Prickett, Jared J Gartner, Jessica S Crystal, Ilana M Roberts,[...]. Nat Med 2016
514
9

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.
Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, Sabrina Schindler, Felix J Hartmann, Lukas M Weber, Reinhard Dummer, Mark D Robinson, Mitchell P Levesque, Burkhard Becher. Nat Med 2018
369
9

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, Adil Daud, F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D Wolchok, Peter Hersey, Richard W Joseph, Jeffrey S Weber,[...]. N Engl J Med 2013
8

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij, Marit M van Buuren, Daisy Philips, Arno Velds, Mireille Toebes, Bianca Heemskerk, Laura J A van Dijk, Sam Behjati, Henk Hilkmann, Dris El Atmioui,[...]. J Clin Oncol 2013
600
8

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Sander Kelderman, Bianca Heemskerk, Harm van Tinteren, Rob R H van den Brom, Geke A P Hospers, Alfonsus J M van den Eertwegh, Ellen W Kapiteijn, Jan Willem B de Groot, Patricia Soetekouw, Rob L Jansen,[...]. Cancer Immunol Immunother 2014
217
8

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
8

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, Bastian Schilling, Sachet A Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H Geukes Foppen, Simone M Goldinger,[...]. Science 2015
8

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, Michael A Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker,[...]. Clin Cancer Res 2016
102
8

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, Robert J Orlowski, Rosemarie Mick, Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R Giles, Brandon Wenz,[...]. Nature 2017
856
8

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
7

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
7

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M Hyams, Henry Gómez, Lars Bastholt,[...]. J Transl Med 2011
398
7

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, David B Page, Sebastian E A Schroeder, Katherine S Panageas, Richard D Carvajal, Paul B Chapman, Gary K Schwartz, James P Allison, Jedd D Wolchok. Cancer 2010
347
7

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J Schwartzentruber, David H Lawson, Jon M Richards, Robert M Conry, Donald M Miller, Jonathan Treisman, Fawaz Gailani, Lee Riley, Kevin Conlon, Barbara Pockaj,[...]. N Engl J Med 2011
593
7

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Véronique Corbière, Jacques Chapiro, Vincent Stroobant, Wenbin Ma, Christophe Lurquin, Bernard Lethé, Nicolas van Baren, Benoît J Van den Eynde, Thierry Boon, Pierre G Coulie. Cancer Res 2011
138
7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
7

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, Alena Gros, Paul F Robbins, Yong-Chen Lu, Mark E Dudley, John R Wunderlich, Robert P Somerville, Katherine Hogan, Christian S Hinrichs,[...]. Science 2014
7

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Ahmad A Tarhini, Howard Edington, Lisa H Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson,[...]. PLoS One 2014
209
7

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
Shigehisa Kitano, Michael A Postow, Carly G K Ziegler, Deborah Kuk, Katherine S Panageas, Czrina Cortez, Teresa Rasalan, Mathew Adamow, Jianda Yuan, Philip Wong,[...]. Cancer Immunol Res 2014
93
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.